Supplementary Material for: Real-World Efficacy and Safety of TACE Combined with Lenvatini

Supplementary material for a multicenter retrospective study of 421 patients with unresectable hepatocellular carcinoma (HCC) from 20 Chinese tertiary hospitals. The data compares triple therapy (TACE, lenvatinib, PD-1 inhibitor) to dual therapy (TACE and lenvatinib) on outcomes including overall survival, progression-free survival, and conversion surgery rates. The study was conducted from January 2019 to June 2023 and published on figshare under a CC-BY-4.0 license.

Use Cases

• Compare overall survival (OS) and progression-free survival (PFS) between dual and triple therapy regimens based on the reported hazard ratios.
• Analyze tumor response rates, including objective response rate (ORR) and complete response rate (CRR), for different treatment combinations.
• Investigate conversion surgery rates as an outcome measure in conversion therapy for unresectable HCC.
• Assess the safety profile of combined therapies based on reported rates of grade 3-4 adverse events and immune-related adverse events.

Strengths

• Data from a multicenter study involving 421 patients across 20 tertiary hospitals.
• Study period spans over four years, from January 2019 to June 2023.
• Analysis includes multiple statistical methods: Inverse Probability of Treatment Weighting (IPTW), propensity score matching, landmark analysis, and E-value analysis.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• The study is retrospective, which the authors note introduces inherent limitations and requires findings to be considered hypothesis-generating.
• Row count for the underlying dataset is unknown, which may limit suitability assessment.

Provenance

Source

Multicenter study conducted in 20 Chinese tertiary hospitals.

Collection Method

Retrospective study of consecutive patients receiving either dual or triple therapy.

Time Range

January 2019 to June 2023

Freshness

Last updated 2026-05-06 05:55:17; freshness should be verified.

Geography

China